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ABSTRACT
Women with osteoporosis treated for 36 months with twice‐yearly injections of denosumab sustained fewer hip fractures compared
with placebo. Treatment might improve femoral bone at locations where fractures typically occur. To test this hypothesis, we used 3D
cortical bone mapping of postmenopausal women with osteoporosis to investigate the timing and precise location of denosumab
versus placebo effects in the hips. We analyzed clinical computed tomography scans from 80 female participants in FREEDOM, a
randomized trial, wherein half of the study participants received subcutaneous denosumab 60mg twice yearly and the others
received placebo. Cortical 3D bone thickness maps of both hips were created from scans at baseline, 12, 24, and 36 months. Cortical
mass surface density maps were also created for each visit. After registration of each bone to an average femur shapemodel followed
by statistical parametric mapping, we visualized and quantiﬁed statistically signiﬁcant treatment effects. The technique allowed us to
pinpoint systematic differences between denosumab and control and to display the results on a 3D average femur model.
Denosumab treatment led to an increase in femoral cortical mass surface density and thickness, already evident by the third injection
(12 months). Overall, treatment with denosumab increased femoral cortical mass surface density by 5.4% over 3 years. One‐third of
the increase came from increasing cortical density, and two‐thirds from increasing cortical thickness, relative to placebo. After
36 months, cortical mass surface density and thickness had increased by up to 12% at key locations such as the lateral femoral
trochanter versus placebo. Most of the femoral cortex displayed a statistically signiﬁcant relative difference by 36 months.
Osteoporotic cortical bone responds rapidly to denosumab therapy, particularly in the hip trochanteric region. This mechanism may
be involved in the robust decrease in hip fractures observed in denosumab‐treated women at increased risk of fracture. © 2014
American Society for Bone and Mineral Research.
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Introduction
Combating the rising epidemic of hip fractures is a key goal inmusculoskeletal research. The FREEDOM study was a large,
randomized clinical trial comparing denosumab (the anti‐
receptor activator of NF‐kB ligand [RANKL] binding monoclonal
antibody treatment) with placebo in postmenopausal women
with osteoporosis. Women treated with denosumab injections
sustained signiﬁcantly fewer hip fractures than those receiving
placebo.(1) The difference in hip fracture events appeared early
(Fig. 1), persisted, and was noteworthy in subjects aged 75 years
and older.(1) Most hip fractures in clinical practice occur because
of falls onto the greater trochanter,(2) and when femurs are
subjected to similar conditions in the lab, the failure of very small
(less than 6.4% of all bone tissue) foci of bone are sufﬁcient to
lead to catastrophic fracture.(3) When FREEDOM study partic-
ipants’ femurs were subjected to sideways fall simulations,
denosumab increased calculated femoral strength by 8.4% over
3 years,(4) perhaps because of focal changes in bone structure. It
is not yet clear how antiresorptives prevent hip fractures in the
early phase of landmark clinical trials such as FREEDOM. It is
possible that the dramatic effects in reducing hip fractures might
be attributable to treatment effects on bone microstructure that
are not detected with in vivo imaging techniques. We favor an
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alternative hypothesis, namely that beneﬁcial effects of anti-
resorptive drugs can be detected in imaging data, particularly in
focal areas known to be associated with hip fracture. To test this,
we investigated the effects of denosumab treatment on cortical
bone throughout the proximal femur, paying particular attention
to the speciﬁc locations where hip fractures have been found to
occur during laboratory simulations.(5–7)
Both cortical and trabecular bone compartments are critical in
determining hip fracture resistance.(8–11) We recently used 3D
cortical bone mapping(12,13) to analyze pelvic computed
tomography (CT) scans from women with and without acute
hip fracture.(14) Women with a femoral neck fracture had a patch
of focal cortical bone thinning in the superior head‐neck junction
of the femur, whereas women with a trochanteric hip fracture
had a patch of focal cortical thinning in the lateral trochanteric
region.(14) Similar areas were also identiﬁed in a prospective
study evaluating 3D density distributions in an Icelandic cohort
who sustained hip fracture.(9) Such defects are anatomically
located in cortical and trabecular areas where femoral neck and
trochanteric fractures occur during laboratory simulations,(15,16)
often coinciding with regions that receive low amounts of
mechanical loading during habitual activities such as walking.(17)
Irrespective of their pathogenesis, focally thin cortical bone in the
hip predicts hip fracture.(18)
In this study, we tested the hypothesis that denosumab would
improve femoral cortical bone structure in those same areas
known to be deﬁcient and associated with increased hip fracture
risk. To investigate this hypothesis, we used 3D cortical bone
mapping(12) to determine the precise location of denosumab
effects in the femurs of women with osteoporosis, surmising that
beneﬁcial effects would correspond with the focally thin areas
identiﬁed previously.(14) We visualized the precise magnitude
and time course of changes in the femoral cortex with
denosumab therapy relative to placebo among participants in
the FREEDOM clinical trial.
Materials and Methods
Cortical bone mapping(12) (Fig. 2) allows us to display local,
pointwisemeasurements of the thickness ormass surface density
as a color map over a patient’s 3D bone surface, with several
thousand independent measurements across each proximal
femur. Surface density is a regional measurement computed at
each measurement point as 0.1 local cortical thickness (mm)
 average cortical bone mineral density (BMD; g/cm3), and
representing mass per unit surface area (g/cm2). When differ-
ences are expressed systematically between femurs from suitably
sized groups of individuals, the technique has sufﬁcient sensitivity
to detect even small changes (30 microns) in thickness with
treatment(19) or between cases and controls.(14) We use it here to
visualize the location of average denosumab treatment effects.
From 2004 to 2009, women aged 60 to 90 years with osteoporosis
deﬁned by dual‐energy X‐ray absorptiometry (DXA) T‐scores
2.5 at the lumbar spine and/or proximal femur were
consented and participated in the FREEDOM study, an interna-
tional, randomized, placebo‐controlled trial. Eligible womenwere
randomly allocated to receive either 60mg denosumab or
placebo by subcutaneous injection every 6months for 3 years. All
women received daily supplements of 1000mg calcium (mini-
mum), and those with insufﬁcient vitamin D were supplemented
with between 400 and 800 IU vitamin D daily. Full details of the
study population are available,(1) but in brief, women currently
taking oral or iv bisphosphonates were excluded, as were those
taking strontium ranelate, parathyroid hormone, steroid hor-
mone‐replacement therapy (HRT), selective estrogen‐receptor
modulators (SERMs), calcitonin, or calcitriol. Participants at
multiple qualiﬁed centers were invited to enroll in a QCT study
and, after providing written informed consent, underwent
standard clinical CT scanning at baseline, 12, 24, and 36 months.
Participants were positioned on an image analysis phantom
(Mindways calibration phantom, Mindways Software Inc., Austin,
TX, USA), and a single CT scan including both hips was performed
from 1 cm above the acetabulum to 2 cm below the lesser
trochanter (120 kV, pitch¼ 1, 170 mAs, reconstruction ﬁeld of
view 400mm, medium kernel, reconstruction slice thickness
1.25mm). CT scan image quality control, scanner calibration,
and stability were monitored by Synarc (Synarc, Hamburg,
Germany). A full description of the imaging protocol and primary
results has been published.(20) After accounting for missing visits
and image quality control, there were 80 hip scans at baseline,
with 79 at 12 months, 78 at 24 months, and 62 at 36 months. Of
Fig. 1. Kaplan‐Meier curves of time to ﬁrst hip fracture in all women (left) and women aged 75 years and older (right) during the FREEDOM clinical trial.
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these, 78 were common between baseline and 12 months, 77
between baseline and 24 months, and 61 between baseline and
36months. Anonymized CT scans were transferred to Cambridge,
and all image processing and analysis steps were performed by
operators blind to treatment allocation. Only tomographic
reconstructions with a large ﬁeld of view completely including
the calibration phantom were considered.
The process for 3D cortical bone mapping is summarized in
Fig. 2. Both femurs were segmented semiautomatically in
Stradwin software (Treece, Gee, Cambridge, UK) before mapping
cortical thickness at approximately 6000 surface points per femur.
Cortical thickness and mass surface density were estimated from
the CT data using the method described by Treece and
colleagues.(12,13) By making reasonable assumptions about both
the anatomy and the imaging blur, thickness can be measured to
super‐resolution accuracy across the entire proximal femur. The
methodology has been validated against thickness measure-
ments obtained from high‐resolutionmicro‐CT scans of cadaveric
femurs.(12,13) The process of measuring cortical thickness and
mass at every vertex on a 3D bone surface was as follows:
Segmentation
Both femurs in each data set were segmented in multiple slices
(at least one every 3mm) of the DICOM data, and the
segmentations used to create a regular triangulated proximal
femoral surface for each femur. The subsequent measurement
points were located at the vertices of these triangles.
Estimating whole femur average cortical density
A single value of average cortical density (mg/cm3) was
estimated for the whole femur, as described in Treece and
colleagues,(13) by reference to the calibration standards in the
Mindways phantom, converting Hounsﬁeld units into mg/cm3 of
bone. This average cortical density value was generated from
both femurs in an individual.
Estimating cortical mass surface density and thickness
At each of the several thousand vertices per femur, the cortical
bone CT data were sampled by automated placement of an
Fig. 2. Summary of the steps involved in 3D cortical bone mapping and analysis of changes over time using statistical parametric mapping (SPM). (1)
Triangulated 3D surface of a left proximal femur (one individual) and corresponding coronal CT plane after segmentation with Stradwin software. (2) An
axial CT slice to demonstrate sampling the CT data along an 18‐mm cyan transcortical line at the surface location indicated by the red circular dot. (3)
Parametric ﬁt (red curve) and original CT data (cyan curve) superimposed on a graph of distance (x axis) versus Hounsﬁeld units (y axis) along the 18‐mm
transcortical line. The cortical thickness is the distance between the red arrows. (4) Many thousands of cortical thickness estimates painted by reference to
a color scale onto the femoral surface of the same individual. (5) Registration (morphing) of the individual’s femoral surface shape to the canonical femur
shape (CFS). (6) Resultant map displaying cortical thickness for the individual now on the CFS after left and right femurs are averaged to give a single map
per participant at each visit. (7) Subtracting the baseline cortical thicknessmap from the 36‐monthmap in an individual to create a differencemap. (8) After
unblinding, there are two groups: cortical thickness differencemaps from the placebo (upper) and denosumab groups (lower). (9) Typical results from one
arm of the study (in this case, the denosumab group) using the statistical parametric mapping process to ﬁnd and quantify where the 36‐month maps
differ from baseline maps. The left image shows a yellow p value map displayed on the CFS. The yellow foci are vertices where cortical thickness changed
signiﬁcantly between baseline and 36 months, ranging from gray (nonsigniﬁcant) via orange to increasingly bright yellow as the p value decreases. The
right image shows the amountof change as a color scale on the CFS. In this hypothetical case, we see increasing thicknesswith denosumab. (10) Final result
showing the magnitude of increase in cortical thickness on the CFS with only areas of statistically signiﬁcantly greater cortical thickness retained, the rest
grayed out. For actual results, see Figs. 4 and 5.
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18‐mm line normal to the surface at that point. This line cut from
outside the bone, through the periosteum, then cortical bone, and
into the endosteal and trabecular compartment. A plot of
Hounsﬁeld units sampled from the CT data on the y axis against
distance along the line on the x axis is shown in Fig. 2. At each
vertex, a six‐parameter model constrained by the peak cortical
bone Hounsﬁeld value within that femur was matched to the
sampled CT data through optimization, giving cortical thickness
(Fig. 2). Multiplying that cortical thickness value (mm)by thewhole
femur’s average cortical density (mg/cm3) gave a value of cortical
bone mass per unit surface area for each vertex (0.1CTh
CBMD). This unit is correctly referred to as surface density (deﬁned
as “a quantity [such asmass or electricity] per unit area distributed
over a surface,” Merriam‐Webster Dictionary, 2014), and here can
be thought of as the total amount of cortical bone (inmg)
contained within the calculated endosteal and periosteal cortical
boundaries beneath a given area (in cm2) of bone surface For an
individual femur, either thickness or mass surface density can be
visualized on the femur surface as a map using a color scale.(13)
Binary ﬁles containing the x, y, and z coordinates of each vertex,
plus the cortical mass surface density or thickness at each vertex
were exported for analysis in Surfstat. A typical 18‐mm‐long
transcortical surface normal and the corresponding parametric ﬁt
model, as well as the sampled CT data constrained by the peak
cortical bone Hounsﬁeld value of 1680 HU can be found in Fig. 2.
Registration
To account for variations in inter‐subject morphology, each map
was spatially realigned with a canonical femur surface using a
B‐spline free‐form deformation calculated by the iterative closest
point registration algorithm.(21) This process maps the nearest
thickness values to the vertices on the canonical femur surface.
The spatially normalizedmapswere then smoothedwith a 10‐mm
full‐width‐half‐maximum ﬁlter. The femoral head was excluded
because the presence of the acetabulum made measurements
here less reliable. The distal end of the analysis plane was deﬁned
by the extent of the common (canonical) shape.
Difference maps
Left and right hip cortical bone maps were averaged for each
visit, creating a single cortical femur map per participant at
baseline, 12‐, 24‐, and 36‐month visits. Each participant’s map
from the 12‐month visit was subtracted from her own baseline
bone map to give a difference map, a process repeated for the
24‐ and 36‐month visits. This resulted in 78 differencemaps (from
78 participants) at 12 months, 77 difference maps at 24 months,
and 61 difference maps at 36 months.
Statistical parametric mapping (SPM) for significance and
magnitude of differences
Information from the study coordinating center was supplied,
indicating which patients were in the denosumab group and
which in the placebo group. Having sorted the difference maps
into those from the drug group and those from the placebo
group, we used SPM to ﬁnd and quantify where the cortical mass
surface density and thickness differed between baseline and
each visit. Surfstat (http://math.mccgill.ca/keith/surfstat/)(22,23)
was used to test whether the difference value at each vertex was
signiﬁcantly different from zero using a ﬁxed‐effects general
linear model. T‐statistics were calculated to test the signiﬁcance
of differences. No allowance was made in the analysis for patient
age, height, or any other demographics because prior and
concurrent work have established not only that there were no
important differences between these parameters in the
FREEDOM QCT study group participants but also that denosu-
mab effects show no age dependency.(24) Random ﬁeld theory
then furnished p values, corrected for multiple comparisons to
control the overall imagewise chance of false positives. These
methods are described fully in two recent articles.(14,19) In the
results ﬁgures, the canonical femur shape is viewed from anterior
and posterior aspects for each visit to show the change in mass
surface density (g/cm2) or in thickness (mm) relative to baseline.
We present difference and signiﬁcance simultaneously, by
retaining only those differences that were statistically signiﬁcant
and graying out the remainder.
Measuring the thickness of the fairly thin cortex of the
proximal femur is challenging in clinical CT data. We have
previously demonstrated that our cortical thickness measure-
ment technique is more accurate than the existing alterna-
tives;(12,13) however, it is important to note that there remains
some ambiguity between measured cortical thickness increases
owing to the ﬁlling in of intracortical pores, or owing to increases
in actual overall cortical thickness. Once blurred by the imaging
system, these two mechanisms can produce identical CT data.
Fig. 3. Percentage changes in overall cortical mass surface density (left), overall cortical thickness (center), and overall cortical density (right) during 3
years’ treatmentwith denosumab or placebo. These results are averaged across the entire femoral cortical surface. (By “overall,”we denote themean value
for all femurs, each averaged over the entire canonical femur surface; ie, the average of approximately 6000 points per femur from 78 femurs [every
femur]). The values are shown for each of four visits (baseline, 12 months, 24 months, and 36 months).
Journal of Bone and Mineral Research DENOSUMAB INCREASES FEMORAL CORTICAL BONE 49
We, therefore, need to be careful in our interpretation of such
cortical thickness increases, and this is discussed in the context of
the results in Discussion.
Results
The basic results of our analyses (Fig. 3, right panel) do not involve
SPM, but simply show the overall group cortical density for drug
and placebo arms plotted over time (see whole femur average
cortical density in the Materials and Methods). In the same ﬁgure,
we show for each study arm the overall average of all surface
measurement points on all femurs for thickness (Fig. 3, center
panel) andmass surface density (Fig. 3, left panel). Comparedwith
baseline, there was a statistically signiﬁcant increase in
overall average cortical mass surface density (þ5.9mg/cm2,
p¼ 3.0 1018, Fig. 3, left panel) and cortical thickness (26mm,
Fig. 4. Scaled color maps showing the changes in femoral cortical mass surface density observed in the placebo group (upper four panels) with the
changes in cortical mass surface density in the denosumab group (lower four panels) after 36 months (n¼ 61). Change is displayed as either absolute
increase at each surface point or percentage increase at each surface point.
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p¼ 3.2 108, Fig. 2 center panel) in women treated with
denosumab for 3 years (six injections). There was also a
statistically signiﬁcant increase in overall average cortical density
(þ23mg/cm3, p¼ 3.4 1012, Fig. 3, right panel) in those
receiving denosumab. There was a reduction in cortical mass
surface density and thickness across much of the femoral surface
in women who received placebo for 3 years, and in some focal
areas, this also reached statistical signiﬁcance by SPM (Fig. 4,
upper panels). Cortical density increased transiently at 12months
in placebo‐treated (calcium/vitamin D–receiving) patients (Fig. 3,
right panel).
In Fig. 4, the color maps of the upper panels highlight the
decrease in absolute and percentage cortical mass surface
density observed with placebo at 36 months, whereas the lower
panels show the increase observed with denosumab. In these
results ﬁgures, only the statistically signiﬁcant differences have
Fig. 5. Scaled color maps showing the changes in femoral cortical thickness observed in the placebo group (upper four panels) with the changes in
cortical thickness for the denosumab group (lower four panels) after 36 months (n¼ 61). Thickness change is displayed as either absolute increase in
cortical thickness (mm) at each surface point or percentage increase at each surface point.
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been retained on the color map. Areas where there were no
statistically signiﬁcant differences are shown as a gray color. The
same scales and anatomical perspectives (anterior and posterior
view) of the average right femur are used in all the ﬁgures. By
3 years, most of the femoral cortex of women treated with
denosumab displayed a statistically signiﬁcant increase in
cortical mass surface density relative to baseline (Fig. 4, lower
panels). Intermediate time‐point data (separate color maps for
12, 24, and 36 months) are shown in Supplemental Figs. S1 to S4.
Color maps of the relative difference (denosumab relative to
placebo group) are shown in Supplemental Figs. S5 and S6. The
largest relative increase with denosumab was in the lateral
greater trochanter (up to 12%) close to the insertion site of the
gluteal muscles. This site plus the inferior femoral neck and
lateral shaft were also notable areas of absolute increase in
cortical mass surface density.
In the lower panels of Fig. 5, the changes in cortical thickness
for the denosumab group at 36 months are displayed. As
mentioned in Materials and Methods, these results could reﬂect
new bone or inﬁlling of intracortical pores in existing bone.
Overall, the extent of the increase in cortical mass surface density
with denosumab was larger than that observed in cortical
Fig. 6. Idealized representation of the effects of a drug on the measurement of thickness in a blurred CT cortex at one vertex (for an example of a single
vertex, see red spot in Fig. 2). The drug progressively increases overall cortical density (HU) at three time points (i, ii, iii). Its other effect might be to add new
bone on endosteal and periosteal surfaces (left panels) or alternatively to ﬁll in extensive intracortical pores (right panels). With current cortical mapping
techniques, both physiological processes would produce an identical increase in measured cortical thickness at that vertex.
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thickness. The largest relative increase in thickness was also
found in the lateral greater trochanter (up to 12%) at the
insertion site of the gluteal muscles.
Discussion
We know that women with osteoporosis (who have generally
thinner and more porous bones) are more likely to suffer hip
fracture. However, rather than studying the overall hip bone
density, it has become scientiﬁcally (and possibly clinically) more
important to assess small focal areas of the femur because high‐
quality simulations show that failure of just 4.5% of bone tissue
in the proximal femur can be enough to cause catastrophic
failure of the femoral neck.(25) This catastrophic failure inevitably
involves the outer cortical bone of the femur,(16) which thins
rapidly with age,(17,26) and is a key determinant of bone strength
and fracture risk,(9,18,26–28) although trabecular bone may be the
ﬁrst site to give way. Cortical bone thinning, in particular, is
partially reversible, as we showed with previous work involving
teriparatide therapy.(19,29) Trabecular bone and subcortical
trabecular bone are also key determinants of bone strength
and fracture risk but have not been studied here. In this study,
we tested the hypothesis that denosumab treatment of women
with osteoporosis would improve cortical bone in regions of
focal thinning and, thus, begin to explain the 8.4% increase in
overall femur strength with treatment shown by modeling. We
found that by 36 months, most of the femoral cortex of
denosumab‐treated women displayed a statistically signiﬁcant
increase in cortical mass surface density, but smaller foci were
already detectable by 12 months. Speciﬁcally, the greatest
relative increase in cortical mass surface density of up to 12%
(Fig. 4) occurred in the lateral trochanter, a site where focal
thinning has been linked with trochanteric fracture.(14) Deno-
sumab also increased cortical mass surface density in the
femoral neck, a site that is important in the pathogenesis of hip
fracture.(5,14) Both femoral neck and trochanteric hip fractures
were reduced by denosumab in the FREEDOM trial (in women
aged 75 years and older, treatment halved the number of
femoral neck fractures and reduced trochanteric fractures by
70%). Because women treated with denosumab had fewer hip
fractures, we speculate that the enhancement of cortical bone at
key at‐risk sites of the femur might have contributed to the
efﬁcacy of the drug.
Cortical bone mapping uses images from clinically acquired
pelvic CT scans, such as those performed on participants in
major osteoporosis trials. We previously discovered that the
technique was effective in identifying focal thickening of
femoral cortical bone during teriparatide treatment of women
with severe osteoporosis.(19) Because there was little change in
cortical mass surface density in that study,(13) it is likely that
new but relatively undermineralized bone had been deposited
or, alternatively, that new bone apposition from teriparatide
administration was associated with increased intracortical
porosity.(12,30) In the present study, denosumab had a large
effect on cortical mass surface density as well as thickness. Mass
surface density can be increased by increasing the deposition
and mineralization of bone or by inﬁlling of pores. We have
already highlighted the difﬁculty of distinguishing cortical
thickness increases owing to increasing true bone thickness
and the inﬁlling of endocortical pores at a histological level.
Fig. 6 shows how ﬁlling‐in of intracortical pores can resemble
increasing absolute thickness using cortical bone mapping, in a
scenario where bone density is also increasing with time.
Denosumab is considered a powerful anticatabolic, strongly
inhibiting osteoclast formation, resorption activity, and en-
hancing bone mineralization through reduced bone remodel-
ing. Cortical thickening is an intriguing and somewhat
counterintuitive ﬁnding, given the expected antiresorptive
proﬁle of denosumab. Previous studies conducted in nonhu-
man experimental models(31) or high‐resolution scans of
peripheral bones of human distal tibias or radii(32) point to
reduced cortical porosity as a therapeutic effect. Our results
add to these by showing that denosumab has both general and
focal effects on enhancing femoral cortical bone thickness
(which might reﬂect inﬁlling of cortical pores; Fig. 4).
A further limitation of the current analysis method is that we
have deliberately focused exclusively on the cortical compart-
ment. There is strong evidence that trabecular bone is critical in
determining fracture resistance.(3) Our bone mapping tech-
nique can now be applied to the trabecular compartment,
and analyzing the effects of osteoporosis drugs on trabecular
bone is a priority for future work. Finally, in this analysis, no
allowance was made for patient age, height, or any other
demographics at baseline, which might have inﬂuenced
results. However, it is highly unlikely that failing to adjust for
baseline values would have a systematic effect on the study
results.
An increase in 3D bone density was also found by Genant and
colleagues using the MIAF femur package (a QCT analysis tool
allowing density estimation in various hip subregions). They
found improvements of 5.4% to 9.9% in volumetric BMD after
denosumab treatment for 3 years, with the highest‐percentage
improvement found in the trabecular compartment, but higher
absolute changes in cortical density.(33) Our analysis adds
spatial information to these results, offering a plausible
explanation for the robust reduction in hip fractures observed
in FREEDOM.
In the present study, we discovered that femoral cortical bone
in women with osteoporosis responds rapidly to denosumab
treatment, particularly in the trochanteric region. This mecha-
nism could enhance resistance to trauma, thereby explaining the
rapid and persisting decrease in hip fractures found in
denosumab‐treated women with osteoporosis.
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